Aoxing Pharmaceutical Company, Inc. (AOXG)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aoxing Pharmaceutical Company, Inc. (AOXG) trades at $0.00 with AI Score 49/100 (Grade C). Aoxing Pharmaceutical Company, Inc. Market cap: $266,756, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for AOXG: AOXG does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AOXG against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
AOXG: the 1 perspectives are evenly split.
How is this calculated? →Aoxing Pharmaceutical Company, Inc. (AOXG) Healthcare & Pipeline Overview
Aoxing Pharmaceutical Company, Inc. is a specialty pharmaceutical company based in China, focusing on narcotic, pain-management, and addiction treatment products, including both herbal and synthetic drugs. With a negative P/E ratio and high gross margin, the company navigates a competitive landscape while developing new pain and addiction treatments.
What Is the Investment Thesis for AOXG?
Aoxing Pharmaceutical Company, Inc. presents a high-risk, high-reward investment profile. The company's focus on the Chinese market for pain management and addiction treatment offers potential growth, especially with its pipeline of drugs like Oxycodone/Acetaminophen and Buprenorphine/Naloxone. However, the company's negative P/E ratio of -183.91 and a negative profit margin of -79.5% raise concerns about its financial stability. Successful navigation of clinical trials and regulatory approvals for its pipeline drugs are key catalysts. Investors should closely monitor the company's progress in these areas, as well as its ability to improve profitability and manage its high beta of -59.16.
Based on FMP financials and quantitative analysis
AOXG Key Highlights
- Market Cap of 267K indicates a micro-cap company with limited resources and higher volatility.
- P/E Ratio of -183.91 reflects the company's current unprofitability, requiring careful evaluation of future earnings potential.
- Gross Margin of 88.1% suggests strong pricing power on existing products, but this needs to translate into overall profitability.
- Beta of -59.16 indicates an inverse correlation with the market, which is unusual and may be due to the stock's illiquidity or unique business model.
- Focus on narcotic, pain-management, and addiction treatment pharmaceutical products in China, a market with significant unmet needs and growth potential.
Who Are AOXG's Competitors?
AOXG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AOXG's Key Strengths?
- Specialized focus on pain management and addiction treatment.
- Established manufacturing capabilities in China.
- Pipeline of drugs in development.
- Existing distribution network within China.
What Are AOXG's Weaknesses?
- Negative profitability and high debt levels.
- Reliance on a single geographic market (China).
- Limited financial resources for R&D and marketing.
- OTC Other tier indicates higher risk.
What Could Drive AOXG Stock Higher?
- Regulatory approval and commercialization of Oxycodone and Acetaminophen tablets and capsules for pain management.
- Positive results from Phase III clinical trials for Buprenorphine/Naloxone in treating opioid dependence.
- Expansion of distribution network within China to reach more patients.
- Increased government support for domestic pharmaceutical companies in China.
- Growing demand for pain management and addiction treatment products in China.
What Are the Key Risks for AOXG?
- Financial-distress signal — its Altman Z-Score of -1.42 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for pipeline drugs.
- Intense competition from established pharmaceutical companies.
- Pricing pressures from generic drug manufacturers.
- Dependence on the Chinese market and regulatory environment.
- Product liability claims and lawsuits.
What Are the Growth Opportunities for AOXG?
- Expansion of Product Portfolio: Aoxing's pipeline of drugs in development, including Oxycodone/Acetaminophen and Buprenorphine/Naloxone, represents a significant growth opportunity. Successful completion of clinical trials and regulatory approvals could lead to new revenue streams and market share gains. The market for pain management and addiction treatment is substantial, with the global market estimated to reach billions of dollars in the coming years. Timeline: 2-5 years for regulatory approvals.
- Geographic Expansion within China: While Aoxing primarily operates in China, there is potential to expand its geographic reach within the country. Targeting specific regions with high demand for pain management and addiction treatment products could drive revenue growth. This expansion could involve establishing new distribution channels and partnerships. Timeline: 1-3 years.
- Strategic Partnerships and Acquisitions: Aoxing could pursue strategic partnerships or acquisitions to expand its product portfolio, geographic reach, or technological capabilities. Collaborating with other pharmaceutical companies or research institutions could accelerate the development and commercialization of new drugs. Timeline: Ongoing.
- Increased Investment in Research and Development: Aoxing could increase its investment in research and development to discover and develop novel drugs for pain management and addiction treatment. This could involve conducting preclinical and clinical studies, as well as collaborating with academic institutions and research organizations. Timeline: Long-term, 5+ years.
- Leveraging Government Support for Domestic Pharmaceutical Companies: The Chinese government is actively supporting the growth of domestic pharmaceutical companies through various policies and initiatives. Aoxing can leverage these policies to access funding, streamline regulatory approvals, and gain a competitive advantage. Timeline: Ongoing.
What Opportunities Does AOXG Have?
- Expanding into new geographic markets.
- Developing new drug formulations and delivery methods.
- Partnering with other pharmaceutical companies.
- Leveraging government support for domestic pharmaceutical companies.
What Threats Does AOXG Face?
- Intense competition from established pharmaceutical companies.
- Stringent regulatory requirements.
- Pricing pressures from generic drug manufacturers.
- Potential product liability claims.
What Are AOXG's Competitive Advantages?
- Proprietary drug formulations and intellectual property.
- Established distribution network within China.
- Expertise in developing and manufacturing narcotic and pain-relief medications.
- Regulatory approvals for its existing products.
What Does AOXG Do?
Aoxing Pharmaceutical Company, Inc., headquartered in Shijiazhuang, China, is a specialty pharmaceutical company dedicated to the research, development, manufacture, and distribution of pharmaceutical products. The company primarily operates in the People's Republic of China, focusing on narcotic, pain-management, and addiction treatment medications. Aoxing’s product portfolio includes Zhongtong'an, a herbal capsule designed for oral and dental pain relief, and Yiqi Qiangshen Granule, an over-the-counter herbal supplement aimed at tonifying qi, empowering the body, and promoting blood circulation. Additionally, the company manufactures Tilidine hydrochloride, a synthetic narcotic analgesic tablet used for moderate to severe pain relief. Further expanding their offerings, Aoxing has several products in development, including Oxycodone and Acetaminophen tablets and capsules, which have completed clinical trials for treating acute and chronic pain. They are also developing Buprenorphine/Naloxone, a sublingual tablet for opioid dependence treatment, which has completed Phase II clinical trials, and Tilidine/Naloxone, a compound capsule in Phase II clinical trials for acute and chronic pain management. Originally known as China Aoxing Pharmaceutical Company, Inc., the company rebranded to Aoxing Pharmaceutical Company, Inc. in March 2010, solidifying its commitment to advancing pharmaceutical solutions.
What Products and Services Does AOXG Offer?
- Researches and develops pharmaceutical products focused on pain management, addiction treatment, and related areas.
- Manufactures narcotic and non-narcotic pain relief medications.
- Produces herbal extraction products for pain relief and general health improvement.
- Distributes its pharmaceutical products primarily within the People's Republic of China.
- Conducts clinical trials for new drug candidates, including treatments for opioid dependence.
- Markets both prescription and over-the-counter (OTC) medications.
How Does AOXG Make Money?
- Develops and manufactures pharmaceutical products.
- Sells prescription and OTC medications through distributors and directly to healthcare providers.
- Generates revenue from the sale of its proprietary drug formulations.
- Invests in research and development to create new products and improve existing ones.
What Industry Does AOXG Operate In?
Aoxing Pharmaceutical Company, Inc. operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and stringent regulatory oversight. The Chinese pharmaceutical market is experiencing rapid growth, driven by an aging population and increasing healthcare spending. However, domestic companies face challenges from international players and evolving regulatory standards. Aoxing's focus on pain management and addiction treatment positions it in a niche market with specific needs, but also heightened regulatory scrutiny. Competitors like AREVF and CWWBF also operate in this space.
Who Are AOXG's Key Customers?
- Hospitals and clinics throughout China.
- Pharmacies and drug stores.
- Patients seeking pain relief and addiction treatment.
- Healthcare providers prescribing medications.
Aoxing Pharmaceutical Company, Inc. Financial Trajectory
Aoxing Pharmaceutical Company, Inc. (AOXG) reported $17K in revenue for Q4 2025, reflecting 727.5% growth compared to the prior quarter. The company recorded a net loss of $11K, with diluted EPS of $0.00.
Company Profile
Aoxing Pharmaceutical Company, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Shijiazhuang, CN. The company is led by CEO Zhenjiang Yue. AOXG has traded publicly since 2005.
How Aoxing Pharmaceutical Company, Inc. Is Valued
Aoxing Pharmaceutical Company, Inc. carries a market capitalization of 267K, placing it in the micro-cap category. Relative to its peer group, AOXG's quantitative score of 49/100 is below the peer average of 66/100.
Key Financial Metrics
Return on assets is -12.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -32.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.96 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -1.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Aoxing Pharmaceutical Company, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.42 places it in the distress zone, a signal of elevated financial risk.
AOXG Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Aoxing's recent insider buying suggests confidence in the company's future prospects, aligning interests with shareholders.
- Community sentiment indicates growing optimism about Aoxing's strategic direction and potential market opportunities.
- The market perception of Aoxing seems to be shifting positively, with increased discussion around its innovative products.
- Recent developments suggest Aoxing is expanding its market reach, potentially leading to increased revenue streams.
Bear Case
- Recent insider selling activity, while not always indicative of bearish sentiment, warrants caution and further investigation.
- Community sentiment reveals concerns about Aoxing's ability to compete effectively in a crowded market.
- Market perception of Aoxing is still somewhat negative due to past performance issues and regulatory challenges.
- Recent developments highlight potential headwinds for Aoxing, including increasing competition and evolving market dynamics.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $17,212 | -$11,201 | $0.00 |
| Q3 2025 | $2,080 | -$2,438 | $0.00 |
Based on FMP financials and quantitative analysis
AOXG Latest News
No recent news available for AOXG.
AOXG Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AOXG.
Price Targets
Wall Street price target analysis for AOXG.
AOXG MoonshotScore
What does this score mean?
The MoonshotScore rates AOXG's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Zhenjiang Yue
CEO
Zhenjiang Yue serves as the CEO of Aoxing Pharmaceutical Company, Inc. He is responsible for overseeing the company's overall strategy, operations, and financial performance. His leadership is crucial in guiding Aoxing through the complex regulatory landscape and competitive market in China. He manages a workforce of 346 employees, focusing on research, development, and manufacturing of pharmaceutical products.
Track Record: Under Zhenjiang Yue's leadership, Aoxing Pharmaceutical Company has focused on developing and commercializing pain management and addiction treatment products. Key milestones include advancing clinical trials for pipeline drugs such as Oxycodone/Acetaminophen and Buprenorphine/Naloxone. The company has also maintained its presence in the Chinese pharmaceutical market despite financial challenges.
AOXG OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Aoxing Pharmaceutical Company, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and viability. Investing in OTC Other stocks carries significantly higher risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Higher risk of fraud and manipulation.
- Potential for delisting or suspension of trading.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or legal disputes.
- Existence of a physical headquarters and operational facilities.
- Presence of a functional website and contact information.
- Patents or intellectual property related to its products.
- Partnerships with reputable organizations or institutions.
- Active engagement with investors and the public.
What Investors Ask About Aoxing Pharmaceutical Company, Inc. (AOXG) — Healthcare
What does Aoxing Pharmaceutical Company, Inc. do?
Aoxing Pharmaceutical Company, Inc. is a specialty pharmaceutical company focused on the research, development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products, primarily in China. Its key products include Zhongtong'an capsules for oral pain, Yiqi Qiangshen Granule for general health, and Tilidine hydrochloride tablets for acute and chronic pain. The company is also developing new treatments for opioid dependence and pain management.
What do analysts say about AOXG stock?
As of 2026-03-17, there is no readily available analyst coverage or consensus for Aoxing Pharmaceutical Company, Inc. due to its OTC Other listing and limited financial disclosure. The company's negative P/E ratio and lack of profitability make valuation challenging. Investors should conduct thorough due diligence and assess the company's growth potential and risk factors independently. The stock's high beta suggests significant volatility.
What are the main risks for AOXG?
Aoxing Pharmaceutical Company, Inc. faces several key risks, including regulatory hurdles in China, intense competition from both domestic and international pharmaceutical companies, and the potential for product liability claims. The company's financial instability, as indicated by its negative P/E ratio and profit margin, also poses a significant risk. Additionally, its OTC Other listing implies limited transparency and liquidity, increasing the risk of price manipulation and delisting.
What are the key factors to evaluate for AOXG?
Aoxing Pharmaceutical Company, Inc. (AOXG) holds an AI score of 49/100 (low). Not financial advice.
How frequently does AOXG data refresh on this page?
AOXG prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AOXG's recent stock price performance?
Aoxing Pharmaceutical Company, Inc. (AOXG) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on pain management and addiction treatment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AOXG overvalued or undervalued right now?
Valuing Aoxing Pharmaceutical Company, Inc. (AOXG) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AOXG?
Before investing in Aoxing Pharmaceutical Company, Inc. (AOXG), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-17.
- OTC Other stocks carry significant risks and require thorough due diligence.
- Financial data may be limited or unaudited.